Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Autoimmune Disorders

  Free Subscription

Articles published in Mult Scler

Retrieve available abstracts of 403 articles:
HTML format

Single Articles

    December 2022
  1. KOSSOWSKI B, Kong Y, Klimiec-Moskal E, Emir U, et al
    Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: Differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes.
    Mult Scler. 2022;28:2221-2230.
    PubMed     Abstract available

    November 2022
  2. SPELMAN T, Ozakbas S, Alroughani R, Terzi M, et al
    Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Mult Scler. 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502.
    PubMed     Abstract available

  3. BROWNLEE WJ, Tur C, Manole A, Eshaghi A, et al
    HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis.
    Mult Scler. 2022 Nov 18:13524585221130941. doi: 10.1177/13524585221130941.
    PubMed     Abstract available

  4. FOLEY J, Xiong K, Hoyt T, Singh CM, et al
    Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
    Mult Scler. 2022 Nov 15:13524585221130949. doi: 10.1177/13524585221130949.
    PubMed     Abstract available

  5. VUKUSIC S, Marignier R, Ciron J, Bourre B, et al
    Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2022 Nov 8:13524585221130934. doi: 10.1177/13524585221130934.
    PubMed     Abstract available

    Cladribine-induced liver injury: Implications for practice.
    Mult Scler. 2022;28:2146.

  7. CAMARA-LEMARROY C, Metz L, Kuhle J, Leppert D, et al
    Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Mult Scler. 2022;28:2081-2089.
    PubMed     Abstract available

  8. KIM JE, Park J, Song TJ
    A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
    Mult Scler. 2022;28:2112-2123.
    PubMed     Abstract available

  9. CACCIAGUERRA L, Mistri D, Valsasina P, Martinelli V, et al
    Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study.
    Mult Scler. 2022;28:2057-2069.
    PubMed     Abstract available

  10. VUKUSIC S, Carra-Dalliere C, Ciron J, Maillart E, et al
    Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
    Mult Scler. 2022 Nov 1:13524585221129472. doi: 10.1177/13524585221129472.
    PubMed     Abstract available

    October 2022
  11. CHERTCOFF A, Ng HS, Zhu F, Zhao Y, et al
    Polypharmacy and multiple sclerosis: A population-based study.
    Mult Scler. 2022 Oct 27:13524585221122207. doi: 10.1177/13524585221122207.
    PubMed     Abstract available

  12. CALOCER F, Ng HS, Zhu F, Zhao Y, et al
    Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis.
    Mult Scler. 2022 Oct 25:13524585221129963. doi: 10.1177/13524585221129963.
    PubMed     Abstract available

  13. DOST-KOVALSKY K, Thiel S, Ciplea AI, Gold R, et al
    Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
    Mult Scler. 2022 Oct 22:13524585221131486. doi: 10.1177/13524585221131486.
    PubMed     Abstract available

  14. CARDENAS-ROBLEDO S, Gonzalez-Caicedo P, Carvajal-Parra MS, Guio-Sanchez CM, et al
    No seasonality in the risk of multiple sclerosis in an equatorial country: A case-control ecological study.
    Mult Scler. 2022 Oct 15:13524585221130020. doi: 10.1177/13524585221130020.
    PubMed     Abstract available

  15. BOURDETTE D, Herink M
    Polypharmacy in multiple sclerosis: More is not necessarily better.
    Mult Scler. 2022 Oct 14:13524585221129964. doi: 10.1177/13524585221129964.

  16. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
    A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS).
    Mult Scler. 2022 Oct 14:13524585221127941. doi: 10.1177/13524585221127941.
    PubMed     Abstract available

  17. KATZ SAND I, Levy S, Fitzgerald K, Sorets T, et al
    Mediterranean diet is linked to less objective disability in multiple sclerosis.
    Mult Scler. 2022 Oct 13:13524585221127414. doi: 10.1177/13524585221127414.
    PubMed     Abstract available

  18. HUISKAMP M, Kiljan S, Kulik S, Witte ME, et al
    Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study.
    Mult Scler. 2022 Oct 3:13524585221125381. doi: 10.1177/13524585221125381.
    PubMed     Abstract available

  19. PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
    Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Mult Scler. 2022;28:1685-1696.
    PubMed     Abstract available

  20. FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
    Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
    Mult Scler. 2022;28:1729-1743.
    PubMed     Abstract available

  21. HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
    The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
    Mult Scler. 2022;28:1710-1718.
    PubMed     Abstract available

  22. CAPANNA M, Signori A, Sormani MP
    Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
    Mult Scler. 2022;28:1744-1751.
    PubMed     Abstract available

  23. ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
    Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
    Mult Scler. 2022;28:1793-1807.
    PubMed     Abstract available

  24. GRAF J, Ng HS, Zhu F, Zhao Y, et al
    Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
    Mult Scler. 2022;28:1825-1828.
    PubMed     Abstract available

  25. SALAMA S, Levy M
    Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:1663-1666.
    PubMed     Abstract available

  26. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.

  27. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    PubMed     Abstract available

  28. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    PubMed     Abstract available

  29. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    PubMed     Abstract available

  30. ECTRIMS 2022 Committees.
    Mult Scler. 2022;28.

    September 2022
  31. BUHLER A, Wolbers M, Model F, Wang Q, et al
    Recurrent disability progression endpoints in multiple sclerosis clinical trials.
    Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
    PubMed     Abstract available

  32. ALEXANDER S, Braisher M, Tur C, Chataway J, et al
    The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
    PubMed     Abstract available

  33. STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
    Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
    PubMed     Abstract available

  34. SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
    Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
    Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
    PubMed     Abstract available

  35. BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
    Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
    Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
    PubMed     Abstract available

  36. POL-PATIL J, Glanz B, Safar L, Misasi E, et al
    MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
    Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
    PubMed     Abstract available

  37. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    PubMed     Abstract available

  38. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    PubMed     Abstract available

  39. VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
    Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
    PubMed     Abstract available

  40. MCGINLEY MP, Lapin B
    The value of patient-reported outcome measures for multiple sclerosis.
    Mult Scler. 2022;28:1489-1490.

    It is imperative to reconsider the concept of seronegative NMOSD.
    Mult Scler. 2022;28:1654-1655.

  42. ROGAWSKI DS, Nirschl JJ, McDonald J, Nie E, et al
    A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma.
    Mult Scler. 2022;28:1651-1654.
    PubMed     Abstract available

  43. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
    The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
    Mult Scler. 2022;28:1606-1619.
    PubMed     Abstract available

  44. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
    The expansion and severity of chronic MS lesions follows a periventricular gradient.
    Mult Scler. 2022;28:1504-1514.
    PubMed     Abstract available

  45. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
    Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Mult Scler. 2022;28:1515-1525.
    PubMed     Abstract available

  46. THEBAULT S, Bose G, Booth R, Freedman MS, et al
    Serum neurofilament light in MS: The first true blood-based biomarker?
    Mult Scler. 2022;28:1491-1497.
    PubMed     Abstract available

  47. PORTACCIO E, Amato MP
    Reliable change indices for cognitive assessment of patients with multiple sclerosis.
    Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.

    August 2022
  48. MEATON I, Altokhis A, Allen CM, Clarke MA, et al
    Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
    Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
    PubMed     Abstract available

  49. BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
    Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
    PubMed     Abstract available

  50. ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
    Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
    Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
    PubMed     Abstract available

  51. YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
    Measuring coping in multiple sclerosis: The Coping Index-MS.
    Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
    PubMed     Abstract available

  52. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
    Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
    PubMed     Abstract available

  53. BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
    Differential vulnerability of thalamic nuclei in multiple sclerosis.
    Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
    PubMed     Abstract available

  54. CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
    Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
    Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
    PubMed     Abstract available

  55. WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
    Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
    Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
    PubMed     Abstract available

  56. CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
    Machine learning classification of multiple sclerosis in children using optical coherence tomography.
    Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
    PubMed     Abstract available

  57. UCCELLI A, Freedman MS
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
    Mult Scler. 2022;28:1326-1328.

    Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
    Mult Scler. 2022;28:1328-1329.

  59. KARUSSIS D, Kassis I, Petrou P
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
    Mult Scler. 2022;28:1324-1326.

  60. GIBBONS E, Whittam D, Elhadd K, Bhojak M, et al
    Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy.
    Mult Scler. 2022;28:1481-1484.
    PubMed     Abstract available

    A rare but distinct and unique phenotype of MOGAD.
    Mult Scler. 2022;28:1485.

  62. SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
    A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
    Mult Scler. 2022;28:1392-1401.
    PubMed     Abstract available

    July 2022
  63. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    PubMed     Abstract available

  64. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
    Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
    PubMed     Abstract available

  65. KLISTORNER S, Barnett MH, Klistorner A
    Mechanisms of central brain atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
    PubMed     Abstract available

  66. JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
    No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
    PubMed     Abstract available

  67. MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
    Changes in prognosis of the Danish multiple sclerosis population over time.
    Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
    PubMed     Abstract available

  68. KRIEGER SC, Antoine A, Sumowski JF
    EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
    Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
    PubMed     Abstract available

  69. ANNA KARIN H, Erik S, Tim S, Lars F, et al
    The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
    Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
    PubMed     Abstract available

  70. LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
    Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
    PubMed     Abstract available

  71. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
    Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
    Mult Scler. 2022;28:1277-1285.
    PubMed     Abstract available

  72. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
    Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
    Mult Scler. 2022;28:1286-1298.
    PubMed     Abstract available

  73. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
    Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
    Mult Scler. 2022;28:1239-1247.
    PubMed     Abstract available

  74. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
    Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Mult Scler. 2022;28:1219-1228.
    PubMed     Abstract available

  75. EISELE P, Wittayer M, Weber CE, Platten M, et al
    Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
    Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
    PubMed     Abstract available

    June 2022
  76. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    PubMed     Abstract available

  77. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    PubMed     Abstract available

  78. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    PubMed     Abstract available

  79. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.

  80. HEMOND CC, Baek J, Ionete C, Reich DS, et al
    Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
    Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
    PubMed     Abstract available

  81. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
    Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
    PubMed     Abstract available

  82. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
    Decentralised clinical trials in multiple sclerosis research.
    Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
    PubMed     Abstract available

  83. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
    Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
    Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
    PubMed     Abstract available

  84. GUERRERA G, Mandelli A, Finardi A, Orrico M, et al
    Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
    Mult Scler. 2022 Jun 20:13524585221102158. doi: 10.1177/13524585221102158.
    PubMed     Abstract available

  85. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
    Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
    Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
    PubMed     Abstract available

  86. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
    PubMed     Abstract available

  87. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
    Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
    Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
    PubMed     Abstract available

  88. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
    Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
    Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.

  89. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
    Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
    PubMed     Abstract available

  90. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
    Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
    PubMed     Abstract available

  91. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    PubMed     Abstract available

  92. CARCAMO C, Ciampi E
    Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
    Mult Scler. 2022;28:1032-1033.

  93. PIEHL F, Mathew T
    Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
    Mult Scler. 2022;28:1028-1029.

    Low-dose rituximab should be used for treating MS in resource-limited settings: No.
    Mult Scler. 2022;28:1030-1032.

  95. WRIGHT S
    MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca's COVID-19 vaccination.
    Mult Scler. 2022;28:1163.

  96. DAMS L, Kraemer M, Becker J
    MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination.
    Mult Scler. 2022;28:1159-1162.
    PubMed     Abstract available

  97. RINALDI V, Bellucci G, Romano A, Bozzao A, et al
    ADEM after ChAdOx1 nCoV-19 vaccine: A case report.
    Mult Scler. 2022;28:1151-1154.
    PubMed     Abstract available

  98. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
    Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Mult Scler. 2022;28:1009-1019.
    PubMed     Abstract available

    May 2022
  99. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
    Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
    Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
    PubMed     Abstract available

  100. FADDA G, Waters P, Woodhall M, Brown RA, et al
    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
    Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
    PubMed     Abstract available

  101. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
    Anti-CGRP therapies for migraine in multiple sclerosis patients.
    Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.

  102. SCHWARZ T, Otto C, Jones TC, Pache F, et al
    Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
    PubMed     Abstract available

  103. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
    Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
    Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
    PubMed     Abstract available

  104. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
    The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
    Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
    PubMed     Abstract available

  105. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
    The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
    PubMed     Abstract available

  106. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
    A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
    Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
    PubMed     Abstract available

  107. HYUN JW, Lee HL, Park J, Kim J, et al
    Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Mult Scler. 2022;28:989-992.
    PubMed     Abstract available

  108. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
    Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
    Mult Scler. 2022;28:885-899.
    PubMed     Abstract available

  109. RENSEL M, Zabeti A, Mealy MA, Cimbora D, et al
    Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial.
    Mult Scler. 2022;28:925-932.
    PubMed     Abstract available

  110. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
    Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Mult Scler. 2022;28:872-884.
    PubMed     Abstract available

  111. ACTRIMS Forum 2022.
    Mult Scler. 2022;28.

    April 2022
  112. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
    Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
    PubMed     Abstract available

  113. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
    Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
    Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
    PubMed     Abstract available

  114. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
    PubMed     Abstract available

  115. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
    Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
    PubMed     Abstract available

  116. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
    Recommendations for the use of propensity score methods in multiple sclerosis research.
    Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
    PubMed     Abstract available

  117. CREE BA, Arnold DL, Fox RJ, Gold R, et al
    Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
    PubMed     Abstract available

  118. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
    Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
    PubMed     Abstract available

  119. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
    Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
    Mult Scler. 2022;28:597-607.
    PubMed     Abstract available

  120. GRATCH D, Zhovtis Ryerson L
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
    Mult Scler. 2022;28:695-696.

  121. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
    Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
    PubMed     Abstract available

  122. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
    Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
    Mult Scler. 2022;28:718-729.
    PubMed     Abstract available

  123. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
    Mult Scler. 2022;28:697-706.
    PubMed     Abstract available

  124. ALY L, Strauss EM, Feucht N, Weiss I, et al
    Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.
    Mult Scler. 2022;28:522-531.
    PubMed     Abstract available

  125. ABDEL-MANNAN O, Klein A, Bachar Zipori A, Ben-Sira L, et al
    Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:676-679.
    PubMed     Abstract available

    Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD.
    Mult Scler. 2022;28:679-680.

  127. KIM KH, Kim SH, Park NY, Hyun JW, et al
    Reappraisal of CSF-specific oligoclonal bands in Asia.
    Mult Scler. 2022;28:665-668.
    PubMed     Abstract available

  128. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
    Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Mult Scler. 2022;28:573-582.
    PubMed     Abstract available

  129. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
    Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
    Mult Scler. 2022;28:550-560.
    PubMed     Abstract available

  130. KIM H, Lee EJ, Kim S, Choi LK, et al
    Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:512-521.
    PubMed     Abstract available

  131. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
    Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
    Mult Scler. 2022;28:620-631.
    PubMed     Abstract available

    March 2022
  132. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
    Association of pregnancies with risk of multiple sclerosis.
    Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
    PubMed     Abstract available

  133. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
    Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
    PubMed     Abstract available

  134. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
    Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
    PubMed     Abstract available

  135. CARLSON A, McGinley MP
    Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
    Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.

  136. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
    Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
    Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
    PubMed     Abstract available

  137. JACOBS BM, Watson C, Marshall C, Noyce A, et al
    No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.

  138. DALGAS U, Stenager E, Hvid LG
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
    Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.

  139. MOTL RW, Sandroff BM
    Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
    Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.

  140. HEESEN C, Rosenkranz SC
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
    Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.

  141. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
    Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
    PubMed     Abstract available

  142. BSTEH G, Hegen H, Berek K, Altmann P, et al
    Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
    Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
    PubMed     Abstract available

  143. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.

  144. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
    Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
    PubMed     Abstract available

  145. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
    Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
    PubMed     Abstract available

  146. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
    Pathways to cures for multiple sclerosis: A research roadmap.
    Mult Scler. 2022;28:331-345.
    PubMed     Abstract available

  147. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
    Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
    PubMed     Abstract available

  148. PITTOCK SJ, Fujihara K, Palace J, Berthele A, et al
    Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Mult Scler. 2022;28:480-486.
    PubMed     Abstract available

  149. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
    Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
    Mult Scler. 2022;28:472-479.
    PubMed     Abstract available

  150. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
    Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Mult Scler. 2022;28:418-428.
    PubMed     Abstract available

    February 2022
  151. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
    The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
    PubMed     Abstract available

  152. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
    Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
    Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
    PubMed     Abstract available

  153. Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
    Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.

  154. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
    Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
    Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
    PubMed     Abstract available

  155. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
    Productivity loss among people with early multiple sclerosis: A Canadian study.
    Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
    PubMed     Abstract available

  156. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
    Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
    PubMed     Abstract available

  157. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
    Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
    PubMed     Abstract available

  158. DOBSON R, Chung K
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Mult Scler. 2022;28:326-327.

  159. COYLE PK, Syritsyna O
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
    Mult Scler. 2022;28:183-185.

  160. BERMEL RA
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
    Mult Scler. 2022;28:185-187.

  161. FOX RJ, Tintore M
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
    Mult Scler. 2022;28:187-188.

  162. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
    A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Mult Scler. 2022;28:237-246.
    PubMed     Abstract available

  163. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
    Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
    Mult Scler. 2022;28:198-205.
    PubMed     Abstract available

  164. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
    Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Mult Scler. 2022;28:257-268.
    PubMed     Abstract available

    January 2022
  165. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
    Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
    Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
    PubMed     Abstract available

  166. NAKAMURA K, Zheng Y, Ontaneda D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
    Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.

  167. MUHLAU M
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
    Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.

  168. ROVIRA A, Pareto D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
    Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.

  169. KEVER A, Riley CS, Leavitt VM
    Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
    Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
    PubMed     Abstract available

  170. P MOSS B, Miller DM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
    Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.

  171. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
    Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
    Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.

  172. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
    Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
    Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
    PubMed     Abstract available

  173. VAN KEMPEN ZL, Hogenboom L, Killestein J
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
    Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.

  174. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
    Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
    PubMed     Abstract available

  175. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
    Mult Scler. 2022;28:16-28.
    PubMed     Abstract available

  176. TARDO L, Wang C, Rajaram V, Greenberg BM, et al
    Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma.
    Mult Scler. 2022;28:160-163.
    PubMed     Abstract available

  177. ABDEL-MANNAN O, Hacohen Y
    Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
    Mult Scler. 2022;28:163-164.

  178. TAJFIROUZ D, Padungkiatsagul T, Beres S, Moss HE, et al
    Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.
    Mult Scler. 2022;28:149-153.
    PubMed     Abstract available

  179. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
    CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
    Mult Scler. 2022;28:71-81.
    PubMed     Abstract available

  180. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
    Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Mult Scler. 2022;28:93-101.
    PubMed     Abstract available

    December 2021
  181. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
    The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
    Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
    PubMed     Abstract available

  182. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
    The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
    Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
    PubMed     Abstract available

  183. CAVACO S, Ferreira I, Moreira I, Santos E, et al
    Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
    Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
    PubMed     Abstract available

  184. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
    Extended dosing of monoclonal antibodies in multiple sclerosis.
    Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
    PubMed     Abstract available

  185. NG HS, Zhu F, Kingwell E, Zhao Y, et al
    Disease-modifying drugs for multiple sclerosis and subsequent health service use.
    Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
    PubMed     Abstract available

  186. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
    Computational basis of decision-making impairment in multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
    PubMed     Abstract available

  187. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
    Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
    Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.

  188. ROLFES L, Meuth SG
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
    Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.

  189. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
    PubMed     Abstract available

  190. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
    Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
    Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
    PubMed     Abstract available

  191. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
    PubMed     Abstract available

  192. ROVIRA A, Corral JF, Auger C, Valverde S, et al
    Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
    Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
    PubMed     Abstract available

  193. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
    Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
    Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
    PubMed     Abstract available

  194. VAN KEMPEN ZL, Killestein J, Hartung HP
    Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
    Mult Scler. 2021;27:2123-2125.

    Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Mult Scler. 2021;27:2290.

  196. LEHMANN H, Zveik O, Levin N, Brill L, et al
    Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
    Mult Scler. 2021;27:2232-2239.
    PubMed     Abstract available

  197. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
    Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
    Mult Scler. 2021;27:2199-2208.
    PubMed     Abstract available

    November 2021
  198. SARKAR P, Redondo J, Hares K, Bailey S, et al
    Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
    PubMed     Abstract available

  199. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
    Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
    Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
    PubMed     Abstract available

  200. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
    Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
    PubMed     Abstract available

  201. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
    Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
    Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
    PubMed     Abstract available

  202. MARRIE RA, McKay K
    Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
    Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.

  203. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
    Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
    Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
    PubMed     Abstract available

  204. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
    Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
    Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
    PubMed     Abstract available

  205. CREE BA, Bennett JL, Kim HJ, Weinshenker BG, et al
    Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Mult Scler. 2021;27:2052-2061.
    PubMed     Abstract available

  206. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
    Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
    Mult Scler. 2021;27:2062-2076.
    PubMed     Abstract available

    October 2021
  207. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    PubMed     Abstract available

  208. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    PubMed     Abstract available

  209. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.

  210. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.

    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.

  212. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    PubMed     Abstract available

  213. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    PubMed     Abstract available

    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.

  215. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    PubMed     Abstract available

  216. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    PubMed     Abstract available

  217. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    PubMed     Abstract available

  218. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    PubMed     Abstract available

  219. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
    Epilepsy as a predictor of disease progression in multiple sclerosis.
    Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
    PubMed     Abstract available

  220. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
    Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
    Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
    PubMed     Abstract available

  221. BSTEH G, Durauer S, Assar H, Hegen H, et al
    Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
    Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
    PubMed     Abstract available

  222. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
    PubMed     Abstract available

  223. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
    Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
    PubMed     Abstract available

  224. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    PubMed     Abstract available

  225. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    PubMed     Abstract available

  226. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    PubMed     Abstract available

  227. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    PubMed     Abstract available

    September 2021
  228. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
    Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
    PubMed     Abstract available

  229. KEVER A, Leavitt VM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
    Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
    PubMed     Abstract available

  230. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
    Risk factors for peripartum depression in women with multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
    PubMed     Abstract available

  231. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
    Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
    PubMed     Abstract available

  232. TREMLETT H, Okuda DT, Lebrun-Frenay C
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
    Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.

    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
    Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.

  234. MAKHANI N
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
    Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.

  235. BRADLEY L
    Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
    PubMed     Abstract available

    Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
    Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.

  237. HARTUNG HP, Meuth SG, Thompson AJ
    Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Mult Scler. 2021;27:1473-1476.

  238. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
    Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
    PubMed     Abstract available

    August 2021
  239. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.

  240. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    PubMed     Abstract available

  241. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    PubMed     Abstract available

  242. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    PubMed     Abstract available

  243. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.

  244. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
    Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
    PubMed     Abstract available

  245. BUTLER PAGNOTTI R, Hua LH, Miller JB
    Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
    PubMed     Abstract available

  246. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
    Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
    Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
    PubMed     Abstract available

  247. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
    SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
    Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.

  248. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
    Functional and structural MRI correlates of executive functions in multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
    PubMed     Abstract available

  249. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
    The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
    PubMed     Abstract available

  250. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
    Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
    Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
    PubMed     Abstract available

  251. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
    Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
    PubMed     Abstract available

  252. AYADI N, Oertel FC, Asseyer S, Rust R, et al
    Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
    PubMed     Abstract available

  253. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
    Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
    PubMed     Abstract available

  254. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
    CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
    PubMed     Abstract available

  255. PANDIT L
    Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
    Mult Scler. 2021;27:1320-1322.

  256. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    PubMed     Abstract available

    July 2021
  257. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
    SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
    Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
    PubMed     Abstract available

  258. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
    High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
    Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
    PubMed     Abstract available

  259. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
    Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
    Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
    PubMed     Abstract available

  260. UHR L, Mateen FJ
    COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
    Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
    PubMed     Abstract available

  261. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
    Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
    PubMed     Abstract available

  262. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
    PubMed     Abstract available

  263. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available

  264. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available

  265. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available

  266. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available

  267. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.

  268. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available

  269. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available

  270. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available

  271. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available

  272. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available

  273. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.

  274. CALDITO NG, O'Leary S, Stuve O
    Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Mult Scler. 2021;27:1306-1308.
    PubMed     Abstract available

  275. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
    Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
    Mult Scler. 2021;27:1284-1292.
    PubMed     Abstract available

  276. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
    Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
    Mult Scler. 2021;27:1187-1197.
    PubMed     Abstract available

  277. OTALLAH S
    Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments.
    Mult Scler. 2021;27:1153-1160.
    PubMed     Abstract available

    June 2021
  278. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available

  279. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available

  280. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available

  281. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available

  282. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available

  283. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available

  284. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available

  285. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available

  286. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available

  287. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available

  288. SCHMIERER K, Giovannoni G
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
    Mult Scler. 2021;27:1006-1007.

    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.

  290. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.

  291. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    PubMed     Abstract available

  292. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    PubMed     Abstract available

  293. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    PubMed     Abstract available

  294. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    PubMed     Abstract available

    May 2021
  295. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available

  296. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available

  297. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available

    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.

  299. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.

    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.

  301. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available

  302. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available

  303. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available

  304. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available

  305. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.

  306. CORREA DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC Junior, et al
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?
    Mult Scler. 2021;27:973-976.
    PubMed     Abstract available

  307. VALENCIA-SANCHEZ C, Flanagan EP
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary.
    Mult Scler. 2021;27:976-977.

  308. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    PubMed     Abstract available

  309. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    PubMed     Abstract available

  310. CACCIAGUERRA L, Rocca MA, Storelli L, Radaelli M, et al
    Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
    Mult Scler. 2021;27:841-854.
    PubMed     Abstract available

  311. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    PubMed     Abstract available

    April 2021
  312. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available

  313. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available

  314. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available

  315. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available

  316. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available

  317. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available

  318. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available

  319. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available

  320. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available

  321. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available

  322. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available

  323. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available

  324. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available

  325. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available

  326. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available

  327. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available

  328. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available

  329. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.

  330. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    PubMed     Abstract available

  331. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    PubMed     Abstract available

  332. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    PubMed     Abstract available

  333. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    PubMed     Abstract available

  334. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    PubMed     Abstract available

    March 2021
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.

  336. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    PubMed     Abstract available

  337. HYUN JW, Kwon YN, Lee HL, Jeong WK, et al
    Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease.
    Mult Scler. 2021;27:449-452.
    PubMed     Abstract available

    February 2021
  338. LUCIANI L, Ninove L, Zandotti C, Chalvignac V, et al
    Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease.
    Mult Scler. 2021;27:320-323.
    PubMed     Abstract available

  339. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    PubMed     Abstract available

  340. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
    Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
    Mult Scler. 2021;27:303-308.
    PubMed     Abstract available

    January 2021
  341. CARNERO CONTENTTI E, Correale J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes.
    Mult Scler. 2021;27:13-15.

  342. JURYNCZYK M, Messina S, Palace J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No.
    Mult Scler. 2021;27:15-16.

  343. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    PubMed     Abstract available

  344. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    PubMed     Abstract available

  345. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    PubMed     Abstract available

    December 2020
  346. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available

    March 2020
  347. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available

  348. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available

  349. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available

  350. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available

  351. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available

  352. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available

  353. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available

  354. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available

  355. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available

  356. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available

  357. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available

    February 2020
  358. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available

  359. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available

  360. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available

  361. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available

  362. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available

  363. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available

  364. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available

  365. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available

  366. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available

    January 2020
  367. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available

  368. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available

  369. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available

  370. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available

  371. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available

  372. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available

    December 2019
  373. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available

  374. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available

  375. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available

  376. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available

  377. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available

    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available

  379. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available

    November 2019
  380. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available

  381. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available

  382. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available

  383. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available

  384. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available

  385. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available

  386. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available

  387. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available

  388. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available

  389. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available

  390. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available

  391. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available

  392. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available

  393. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available

    October 2019
  394. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available

  395. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available

  396. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available

  397. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available

  398. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available

  399. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available

  400. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available

  401. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available

  402. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available

    June 2019
  403. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.